Relapsing Remitting Multiple Sclerosis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for relapsing remitting multiple sclerosis. 48 active patents protecting 4 drugs from 3+ originators. First major cliff: 2028. Daily refresh.

4
Approved drugs
48
Active US patents
66/100
Avg vulnerability
$5.7B
Annual revenue covered

Originators in Relapsing Remitting Multiple Sclerosis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Biogen 18 patents Novartis 15 patents Sanofi 12 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating relapsing remitting multiple sclerosis. Each bar = one year. Y-axis scaled to peak year (16 patents).

2
26
2
27
5
28
5
30
2
31
3
32
4
34
16
35
6
36
1
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Tecfidera
DIMETHYL FUMARATE
 Biogen 18 65 $2.8B 2028-02-07
Mayzent
SIPONIMOD
 Novartis 15 59 $1.1B 2028-08-27
Aubagio
TERIFLUNOMIDE
 Sanofi 12 68 $1.1B 2026-09-12
Leustatin
CLADRIBINE
 — 3 73 $700M 2038-11-23

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
6794410 Aubagio method of use 85 2026-09-12
6794410 Aubagio method of use 85 2026-09-12
6794410 Aubagio other 80 2027-03-12
6794410 Aubagio other 80 2027-03-12
8399514 Tecfidera method of use 80 2028-02-07
8399514 Tecfidera method of use 80 2028-02-07
12533340 Mayzent method of use 75 2036-04-23
11944602 Mayzent method of use 75 2036-04-23
11944602 Mayzent method of use 75 2036-04-23
11944602 Mayzent method of use 75 2036-04-23

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
7939519 Mayzent composition of matter 17 2028-08-27
7939519 Mayzent composition of matter 17 2028-08-27
7939519 Mayzent composition of matter 17 2028-08-27
8802735 Aubagio formulation 53 2030-09-14
8802735 Aubagio formulation 53 2030-09-14
12071402 Mayzent formulation 61 2032-01-05
12071402 Mayzent formulation 61 2032-01-05
12071402 Mayzent formulation 61 2032-01-05
11007166 Tecfidera method of use 62 2035-11-16
11007167 Tecfidera method of use 62 2035-11-16

Related